My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
ALLERGAN
Clerk
>
Contracts / Agreements
>
A
>
ALLERGAN
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
4/12/2023 3:20:14 PM
Creation date
4/12/2023 3:19:29 PM
Metadata
Fields
Template:
Contracts
Company Name
ALLERGAN
Contract #
A-2023-060-05
Agency
City Attorney's Office
Council Approval Date
4/4/2023
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
12
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
DocuSin Envelope ID: B15AAEBD-74AB-4EFF-B97F-0776E33BOD86 <br />iNSURAIviE u'. REQUIRED <br />A-2023-060-05 <br />WORK M=.Y ROCEED <br />Proposed California State -Subdivision Agreement <br />CLERK OF THE COUNCIL Regarding Distribution and Use of <br />Settlement Funds — Allergan Settlement <br />DATE: <br />1. Introduction <br />m <br />C`J <br />Pursuant to the Allergan Settlement Agreement, dated as of November 22, 2022, and any <br />N revision thereto (the "Allergan Settlement Agreement'), including Section VIII and Exhibit O, <br />the State of California proposes this agreement (the "CA Allergan Allocation Agreement') to <br />a govern the allocation, distribution, and use of Settlement Fund payments made to California <br />�t pursuant to Sections VI, VII, and VIII of the Allergan Settlement Agreement. For the avoidance <br />of doubt, this agreement does not apply to payments made pursuant to Sections XII or XIII of <br />the Allergan Settlement Agreement. <br />Pursuant to Exhibit O, Paragraph 4, of the Allergan Settlement Agreement, acceptance of this <br />CA Allergan Allocation Agreement is a requirement to be an Initial Participating Subdivision.' <br />Further, pursuant to Sections X.B and X.0 of the Teva Settlement Agreement and Sections IX.B <br />and IX.0 of the Allergan Settlement Agreement, eligible Subdivisions must participate in both <br />the Teva Settlement Agreement and Allergan Settlement Agreement, or neither.' <br />2. Definitions <br />a) CA Participating Subdivision means a Participating Subdivision that is also (a) a <br />Plaintiff Subdivision and/or (b) a Subdivision with a population equal to or greater <br />than 10,000. For the avoidance of doubt, eligible CA Participating Subdivisions are <br />those California subdivisions listed in Exhibit C (excluding Litigating Special <br />Districts) and/or Exhibit I to the Allergan Settlement Agreement. <br />b) Teva Settlement Agreement means the Teva Settlement Agreement dated November <br />22, 2022, and any revision thereto. <br />c) CPS Settlement Agreement means the CVS Settlement Agreement dated December 9, <br />2022, and any revision thereto as well as any modification thereto entered into by the <br />State of California and CVS. <br />d) Distributor Settlement Agreement means the Distributor Settlement Agreement dated <br />July 21, 2021, and any revision thereto. <br />e) Janssen Settlement Agreement means the Janssen Settlement Agreement dated July <br />21, 2021, and any revision thereto. <br />r A parallel but separate agreement (the "CA Teva Allocation Agreement') will govern the <br />allocation, distribution, and use of settlement fund payments under the Teva Settlement <br />Agreement. <br />' However, if Teva enters bankruptcy prior to the Effective Date, an eligible Subdivision can <br />choose to only join the Allergan Settlement Agreement. <br />
The URL can be used to link to this page
Your browser does not support the video tag.